Maxim Receives $1 Million Development Milestone Payment

Maxim Pharmaceuticals, Inc. reported that it achieved a $1 million development milestone under an agreement with Myriad Genetics. The milestone is based on the dosing of the first patient in a Phase I clinical program designed to evaluate the safety and pharmacokinetic profile of MPC-6827 in patients with advanced solid tumors.
Big News Network